Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2018.03.20
Active substance: radium 223 dichloride
The company Bayer AG issues information that an interim analysis of the randomised clinical trial in patients with castration-resistant metastatic prostate cancer has shown an increased risk of deaths and fractures in patients receiving radium 223 dichloride (Xofigo®) in combination with abiraterone acetate (Zytiga®) and prednisone/prednisolone.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN